May 14th, 2014
Informed Interpretation of the 20-Year Results of the DIGAMI Trial
Valentin Fuster, MD
Darren McGuire gives us his perspective on the DIGAMI trial results.
NEJM — Recent Cardiology Articles- Last Man Running August 8, 2026As the health of his brother and running buddy rapidly declines and he faces his own health scares, a physician feels compelled — and grateful — to keep moving forward.
- Finerenone in Persons with Chronic Kidney Disease without Diabetes August 6, 2026In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months.
- Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD August 6, 2026In a patient with Duchenne muscular dystrophy, cardiotoxic effects developed after treatment with delandistrogene moxeparvovec. Microdystrophin levels in the heart and skeletal muscle were less than 1% of normal dystrophin levels.
- Mineralocorticoid Receptor Antagonism — FINDing Another Benefit August 6, 2026Aldosterone plays a critical role in the homeostasis of blood pressure and volume by engaging mineralocorticoid receptors in the kidneys, heart, and other organs.1 However, overactivation of mineralocorticoid receptors contributes to the pathogenesis of chronic kidney disease (CKD) and heart failure, in part by causing inflammation and fibrosis....
- Oxygen Targets after Cardiac Arrest — A LOGICAL Finding August 6, 2026In unresponsive patients after cardiac arrest, a complex pathophysiological response including potential brain injury, myocardial dysfunction, and systemic ischemia–reperfusion injury is at play, in addition to the challenges of the underlying cause of cardiac arrest.1 This complex and unique, but heterogeneous, constellation has prompted clinicians and researchers to...
- Last Man Running August 8, 2026